PwPepwise

Glutathione

Antioxidants

a.k.a. GSH

Tripeptide antioxidant (Glu-Cys-Gly)

Glutathione is a small tripeptide molecule — composed of three amino acids (glutamate, cysteine, and glycine) — that the body produces naturally.

§Dosing at a glance

2 protocols · from the research
What it's forDoseHow oftenHowFor how long
Oral supplementation500 mg/dayDailyOralTaken by mouth.120 days
Sublingual100 mgTwice daily—4 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Glutathione is a small tripeptide molecule — composed of three amino acids (glutamate, cysteine, and glycine) — that the body produces naturally and uses as its primary internal antioxidant. It plays a central role in neutralizing harmful free radicals, supporting immune function, detoxifying environmental toxins and medications, and maintaining the balance of oxidative stress throughout the body. Circulating glutathione levels tend to decline with age, chronic illness, and poor diet, making supplementation an area of growing scientific interest.

Researchers are actively investigating exogenous glutathione across a broad range of clinical contexts. Inhaled glutathione is being studied as a potential therapy for cystic fibrosis, where impaired glutathione transport in the airways is a recognized feature of the disease1,7. Intranasal delivery is being explored for Parkinson's disease, leveraging the route's potential to reach brain tissue more directly5,17. Oral supplementation is under investigation for skin pigmentation, metabolic conditions including type 2 diabetes, and immune resilience in older adults3,9,11,14. Glutathione also appears to rise naturally as a physiological response to structured exercise in post-stroke patients, suggesting a broader role as a marker of antioxidant health4. The evidence base across these indications is actively developing, with multiple registered clinical trials underway.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Glutathione (GSH) is a tripeptide comprised of L-glutamate, L-cysteine, and glycine, synthesized intracellularly in a two-step ATP-dependent process catalyzed by glutamate-cysteine ligase (GCL) and glutathione synthetase (GS). It is the most abundant non-protein thiol in mammalian cells, present at millimolar concentrations intracellularly, and functions as the central hub of cellular redox homeostasis. Its primary biochemical role is as a direct electron donor: the thiol (-SH) group of the cysteine residue is oxidized to form glutathione disulfide (GSSG), which is subsequently reduced back to GSH by glutathione reductase (GR) using NADPH as a cofactor, completing the redox cycle.

Glutathione serves as an essential cofactor for the glutathione peroxidase (GPx) enzyme family, which catalyzes the reduction of hydrogen peroxide and lipid hydroperoxides, directly limiting oxidative damage to cellular membranes and DNA. It also supports the glutathione S-transferase (GST) superfamily, which conjugates GSH to electrophilic compounds and xenobiotics to facilitate their hepatic and renal elimination — positioning glutathione as a key player in phase II drug detoxification. Additionally, GSH participates in protein glutathionylation, a reversible post-translational modification that protects cysteine residues from irreversible oxidation and serves as a redox signaling mechanism.

In the context of cystic fibrosis, the cystic fibrosis transmembrane conductance regulator (CFTR) has been identified as a channel mediating glutathione transport across airway epithelial membranes. Dysfunctional CFTR results in markedly reduced epithelial lining fluid GSH concentrations, contributing to chronic oxidative stress and amplified inflammatory responses in the CF lung1,7. Aerosol-administered glutathione may restore luminal GSH concentrations above baseline, potentially achieving supraphysiological augmentation rather than mere repletion1.

In the central nervous system, endogenous glutathione is a critical neuroprotective molecule; its depletion is implicated in the pathophysiology of Parkinson's disease through mitochondrial dysfunction and dopaminergic neuron vulnerability to oxidative damage. Intranasal delivery has been proposed to exploit olfactory and trigeminal nerve pathways to bypass the blood-brain barrier and deliver GSH directly to CNS tissue5,17. Systemically, structured exercise has been shown to significantly elevate serum GSH in post-stroke patients with cognitive impairment, with concurrent reductions in the inflammatory marker IL-6, suggesting exercise-induced antioxidant upregulation as a physiologically meaningful biomarker response4.

Oral bioavailability of intact glutathione tripeptide represents a key pharmacokinetic challenge. Conventional oral GSH is subject to hydrolysis by gamma-glutamyl transpeptidase in the gut lumen, limiting systemic delivery of the intact molecule. Novel delivery strategies under investigation include liposomal encapsulation12,18, micellar formulations15, sublingual administration19, bioavailability-enhancing excipients (chitosan, PEG, tannin)9, and ultrasound-enhanced transdermal delivery16 — each designed to improve the fraction of intact GSH reaching systemic circulation or target tissues.

§04Evidence & efficacy

Evidence base
387Studies
157Human
44Animal

The clinical evidence base for glutathione as a therapeutic agent spans multiple indications and delivery routes, and is actively developing across several registered trials.

Cystic Fibrosis (Inhaled): Inhaled glutathione may improve pulmonary function and reduce oxidative stress and inflammation in CF patients, supported by the mechanistic rationale that CFTR dysfunction impairs glutathione transport across airway epithelia and that aerosol administration may elevate epithelial lining fluid glutathione concentrations1,7. Human efficacy data are emerging through ongoing trials.

Parkinson's Disease (Intranasal): Intranasal glutathione is being investigated as an add-on neuroprotective and antioxidant therapy in Parkinson's disease, with the intranasal route proposed to facilitate CNS delivery and bypass the blood-brain barrier5,17. A Phase IIb RCT and a Phase II double-blind placebo-controlled study are registered for this indication, with results pending5,17.

Skin Pigmentation (Oral/Topical): Oral glutathione has been evaluated as a skin-whitening agent in multiple registered double-blind placebo-controlled trials in Southeast Asia, with objective colorimetric and facial analysis endpoints3,10. Glutathione-assisted transdermal delivery for melasma is also under investigation via ultrasound enhancement and microneedling16,20.

Chemotherapy-Induced Peripheral Neuropathy: Glutathione has been studied as a chemoprotective agent to prevent paclitaxel/carboplatin-induced peripheral neuropathy in a Phase III RCT design2, with results pending publication.

Oxidative Stress and Metabolic Health: Oral glutathione supplementation for reducing oxidative damage markers and potentially improving glycemic control in type 2 diabetes is under investigation9. In liver disease, supplementation targeting impaired endogenous GSH synthesis is being evaluated6.

Exercise and Neurological Biomarkers: Serum glutathione has been shown to increase significantly as a physiological response to structured exercise in post-stroke patients with cognitive impairment, alongside favorable changes in BDNF and IL-64, suggesting glutathione as a relevant antioxidant biomarker in neurological recovery contexts.

Endothelial Function: Sublingual glutathione has been explored for improving flow-mediated dilation as a surrogate for endothelial function in smokers and hypertensive patients, addressing the known limitation of oral degradation through an alternative delivery route19.

§05Safety

Across the registered clinical trials and study protocols reviewed, glutathione has been generally administered with an anticipated favorable tolerability profile, and no specific adverse events have been reported in the available records — which largely represent trial registrations rather than completed published safety data.

Oral glutathione at 500 mg/day appears to be well tolerated based on its inclusion in trials targeting vulnerable populations including older adults11,14 and patients with liver cirrhosis or hepatocellular carcinoma6, where safety monitoring included standard biochemical panels (renal and hepatic function markers, lipids, fasting glucose)19. Sublingual administration at 100 mg twice daily similarly included biochemical safety monitoring19. Intranasal delivery of glutathione is considered a low-risk administration route5,17. Inhaled glutathione has been advanced through multi-week protocols in cystic fibrosis patients without reported safety concerns in the available abstracts1,7. Liposomal and micellar formulations are being evaluated for pharmacokinetic and safety profiles in healthy volunteers12,15. In the context of blood product pathogen reduction, glutathione serves as a quenching agent for the alkylating compound amustaline; this application has prior safety experience with red blood cell concentrates informing the first whole-blood application13.

Formal human safety outcome data from completed, published trials are still emerging across all indications, and long-term safety data are an active area of investigation.

§06History

Glutathione was first isolated from yeast by Frederick Gowland Hopkins in 1921, who initially proposed it as a dipeptide before its tripeptide structure (glutamate-cysteine-glycine) was definitively established by Edward Calvin Kendall and colleagues in the 1930s. Its role as the cell's primary antioxidant defense system was progressively elucidated through the mid-20th century, with the identification of the glutathione peroxidase and glutathione S-transferase enzyme families establishing GSH as central to both oxidative stress management and xenobiotic detoxification.

Therapeutic interest in exogenous glutathione administration emerged in the latter decades of the 20th century, initially focused on intravenous delivery in oncology as a chemoprotective agent to mitigate platinum-compound and taxane toxicities — reflected in the Phase III RCT registered to evaluate GSH against paclitaxel/carboplatin-induced peripheral neuropathy2. Inhaled glutathione for cystic fibrosis emerged as a research priority in the 2000s, grounded in the discovery that CFTR dysfunction impairs airway GSH transport, with pilot studies informing the design of formal RCTs registered in this period1,7.

Interest in intranasal glutathione for Parkinson's disease developed through the 2010s, driven by evidence of GSH depletion in the substantia nigra and the need for CNS-penetrant delivery strategies17,5. Concurrently, oral and sublingual formulation research expanded, with investigations in skin pigmentation3,10, cardiovascular risk12,19, immune function in aging11,14, and metabolic disease9. The current research landscape features multiple active registered trials across these indications, with innovative delivery systems — liposomal, micellar, sublingual, intranasal, and ultrasound-enhanced transdermal — reflecting a maturing field working to overcome the bioavailability challenges that have historically limited oral glutathione's clinical translation12,15,16,19.

§07References